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Aim To determine the prevalence and types of persistent 
dyslipidemia in patients treated with different statins to 
reduce cardiovascular disease (CVD) risk, as well as to de-
termine the proportion of high risk patients who did not 
reach the lipid target values and assess cardiologists’ fur-
ther treatment advice for these patients.
Methods This cross-sectional, observational study recruit-
ed 1849 outpatients from all parts of Croatia between Jan-
uary and September 2011 (44.6% women), 19 to 90 years 
old (average age 63.13) treated with statins for at least 6 
months. We analyzed how the potency and type of lipid-
lowering treatment were correlated with CVD risk level and 
achieving treatment goals according to 2007 Joint Euro-
pean Guidelines on CVD prevention.
Results Most patients (81.3%) were at high risk for CVD. 
The most frequently used statin was atorvastatin (42.8%), 
followed by simvastatin (27.6%) and rosuvastatin (22.8%). 
Only 35.5% patients achieved low density lipoprotein-
cholesterol treatment target. Patients treated with more 
potent statins had better results. A total of 22.3% of pa-
tients had high density lipoprotein-cholesterol below 1.0 
mmol/L ( ~ 40 mg/dL) for men and below 1.2 ( ~ 45 mg/dL) 
for women and 46.4% had triglycerides above 1.7 mmol/L 
( ~ 150 mg/dL) but there were no significant differences be-
tween statins in improving these parameters. Most of the 
patients on more potent statins were not advised by their 
cardiologists to change the type or dosage of statin, which 
was more common in patients on less potent statins.
Conclusion A considerable number of patients treated 
with statins did not achieve the treatment goal values. The 
results were better in patients treated with more potent st-
atins and cardiologists advised them much less frequently 
to change the type and dosage of statin. There is a need 
for more intensive treatment, especially for high-risk pa-
tients. This could be accomplished by optimizing patients’ 
adherence, using more potent statins, titrating current sta-
tin therapy to higher doses, or using a combined lipid-low-
ering treatment.
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Dyslipidemia is one of the most important risk factors for 
cardiovascular disease (CVD). According to epidemiologi-
cal data in the US, 29.2% of persons aged 45 to 84 years 
without clinical CVD have dyslipidemia (1). In Croatia, 
about 80% of persons without CVD have total cholester-
ol >5.0 mmol/L ( ~ 190 mg/dL), more than 70% have low 
density lipoprotein (LDL)-cholesterol >3.0 mmol/L ( ~ 115 
mg/dL), almost 50% have triglycerides >1.7 mmol/L 
( ~ 150 mg/dL), and about 20% have high density lipo-
protein (HDL)-cholesterol <1.0 mmol/L ( ~ 40 mg/dL) for 
men and <1.2 mmol/L ( ~ 45 mg/dL) for women (2). An 
adequate treatment of dyslipidemia significantly reduces 
the risk for CVD. Epidemiological studies, as well as an-
giographic or clinical trials, confirmed that a reduction of 
total and LDL-cholesterol, must be of prime concern in 
both primary and secondary prevention of CVD (3,4). It 
has been shown that 10% reduction of plasma total cho-
lesterol is followed by a 25% reduction of coronary artery 
disease incidence after 5 years, and that a reduction of 
LDL-cholesterol for 1 mmol/L is accompanied by a 21% 
reduction of CVD mortality and non-fatal myocardial in-
farction (5,6).
The Fourth Joint European Task Force Guidelines on cardio-
vascular disease prevention in clinical practice (7) defined 
the target treatment levels for total and LDL-cholesterol 
and also suggested optimal levels of HDL-cholesterol and 
triglycerides. Reaching target lipid levels is of utmost im-
portance for reduction of cardiovascular risk.
Statins are widely prescribed for reducing total and LDL-
cholesterol and, with much less effect, triglycerides, as 
well for mildly to moderately increasing HDL-cholester-
ol (3). There are very few data on the prevalence of sta-
tin-treated patients who have achieved lipids treatment 
goal levels according to Fourth Joint European Task Force 
Guidelines in Europe and there are no such data for Croa-
tia. Also, there are no data on cardiologists’ further treat-
ment decisions for patients who have not achieved tar-
get lipids levels.
The aims of this study were to determine the proportion 
of patients who reached the optimal levels of total and 
LDL-cholesterol according to the Fourth Joint European 
Task Force Guidelines on cardiovascular disease preven-
tion in clinical practice after at least 6 months of statin 
therapy, to determine the proportion of patients with 
high cardiovascular risk who reached these levels (7), 
and to determine cardiologists’ further treatment ad-
vice for these patients.
METhods
This cross-sectional observational survey included 154 
cardiologists from all parts of Croatia who were consecu-
tively selected from the Croatian cardiac society’s direc-
tory. They were not reimbursed for the participation. The 
country was divided into five geo-economic regions and a 
consecutive sample of cardiologists from each region was 
obtained. If a cardiologist declined, consecutive sampling 
continued until the required number of cardiologists (at 
least 50% for each region) was achieved. The sample of 
cardiologists is a representative one since there were 286 
licensed cardiologists in Croatia at the time of the study. 
The cardiologists consecutively enrolled patients aged 
18 years or older who came to consultations and were 
treated with any statin available in Croatia (rosuvastatin, 
simvastatin, atorvastatin, lovastatin, and fluvastatin) for at 
least last six months and without changing the dose for 
at least the last 4 weeks (up to at least first 10 patients 
starting from the beginning of the survey). We excluded 
the patients who had been participating in any clinical in-
terventional study during the previous 12 months. All the 
data were collected from clinical examinations and medi-
cal charts from single outpatient visits between January 
and September 2011.
Information was collected on the demographic charac-
teristics (age, sex etc), serum lipid profile (total and LDL-
cholesterol, HDL-cholesterol, triglycerides), and HbA1c at 
the time of consultation, the name and daily dosage of 
the current statin, duration of statin treatment, patients’ 
and family medical history of diabetes mellitus, and risk 
factors for CVD.
At the patient’s visit, it was recorded whether patients 
reached the target levels considering their risk level (high 
or low risk), as well as their compliance with the dosage 
during the last four weeks based upon their report at the 
interview and the cardiologist’s advice about further lipid-
lowering treatment. According to the Fourth Joint Europe-
an Task Force Guidelines, patients at high risk were defined 
as those with pre-existing CVD, diabetes and/or system-
atic coronary risk evaluation (SCORE)≥5%, and patients at 
low-risk were defined as those without these conditions or 
SCORE<5% (5). The study was approved by the Central Cro-
atian National Ethics Committee. All patients signed the in-
formed consent form. Statistical analysis was performed 
using the SPSS 13.0 package (SPSS Inc., Chicago, IL, USA). 
We used two-way ANOVA, t test, or χ2 test as appropriate. P 
value lower than 0.05 was considered significant.
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REsulTs
We analyzed the data of 1811 out of 1849 outpatients. Thir-
ty-eight patients were excluded due to missing data – 12 
due to missing data about the date of the blood sampling, 
25 due to missing data about the date of change of either 
dose or statin type, and 1 due to missing data about age. 
The mean age of patients was 63.13 years (median 64 years) 
ranging from 19 to 90 years, and 44.6% were women.
Most patients (81.3%) were at high risk for CVD. Of those, 
56.9% had pre-existing coronary heart disease (CHD), 
14.4% had peripheral artery disease, 13.1% had cerebro-
vascular disease, and 42.1% had diabetes mellitus.
The most frequently used statin was atorvastatin (42.8% of 
patients), followed by simvastatin (27.6%), and rosuvastatin 
(22.8%). Much fewer patients were taking fluvastatin (5.8%) 
and lovastatin (0.6%), while data for 0.3% of patients were 
not available.
Only 35.5% patients achieved LDL-cholesterol target lev-
el and only 33.4% achieved total cholesterol target level 
(34.0% and 32.3% of those with high CVD risk respectively). 
However, 44.4% of patients taking rosuvastatin and 39.3% 
of those taking atorvastatin reached LDL-cholesterol tar-
get value compared to 25.0% of those taking simvastatin 
or 24.2% of those taking fluvastatin. The results were signif-
icant for rosuvastatin vs simvastatin (P ≤ 0.0001), rosuvas-
tatin vs fluvastatin (P ≤ 0.0001), atorvastatin vs simvastatin 
(P ≤ 0.0001), and atorvastatin vs fluvastatin (P ≤ 0.0001). A 
total of 37.9% of patients on rosuvastatin, 37.1% of those 
on atorvastatin, 25.7% of those on simvastatin, and 25.7% 
of those on fluvastatin reached total cholesterol target 
level. The difference in achieving the total cholesterol tar-
get level was significant for rosuvastatin vs simvastatin 
(P ≤ 0.0001) and rosuvastatin vs fluvastatin (P = 0.013) but 
also for atorvastatin vs simvastatin (P ≤ 0.0001) and atorvas-
tatin vs fluvastatin (P = 0.020).
In patients with high CVD risk, only 34.0% reached LDL-
cholesterol target level and only 32.3% reached total cho-
lesterol target level. Of these patients, 42.6% of those treat-
ed with rosuvastatin reached the target LDL-cholesterol 
level, which was more than 36.7% of those treated with 
atorvastatin, 25.3% of those treated with simvastatin, or 
25.0% of those treated with fluvastatin. The difference in 
achieving LDL-cholesterol target level was significant for 
rosuvastatin vs simvastatin (P ≤ 0.0001) and rosuvastatin vs 
fluvastatin (P = 0.002) but also for atorvastatin vs simvasta-
tin (P = 0.002) and atrovastatin vs fluvastatin (P = 0.026). The 
difference in achieving total cholesterol target level was 
significant for rosuvastatin vs simvastatin (P = 0.001) but 
also for atorvastatin vs simvastatin (P ≤ 0.0001).
A total of 22.3% of patients on statins had low HDL-cho-
lesterol and 46.4% had elevated triglycerides (24.0% and 
46.8% of those with high CVD risk, respectively). There 
were no significant differences between different statins in 
improving these parameters.
There were 51.1% of patients who fully complied with the 
prescribed dose, 34.8% complied with more than 70% of 
the prescribed dose, 7.6% with between 50% and 70% of 
the prescribed dose, 3.0% with between 30% and 50% of 
the prescribed dose, 1.8% with less than 30% of the pre-
scribed dose, and 1.3% were not taking the prescribed sta-
tin at all. For 0.4%, the data were missing (Figure 1).
Concerning the cardiologists’ further treatment advice for 
patients who did not reach target cholesterol levels, 56.2% 
of patients on fluvastatin and 39.0% of patients on sim-
vastatin were recommended to change the type of sta-
tin. This was significantly more than 22.3% of patients on 
atorvastatin or 18.9% of those on rosuvastatin (P ≤ 0.0001). 
On the other hand, most of patients on rosuvastatin treat-
ment were advised to continue with the same statin with-
FiguRE 1. Compliance with the prescribed statin therapy: the 
percentage of the recommended statin dose taken by the 
patient in the last 30 days (1811 patients).
FiguRE 2. The percentage of patients in whom the statin dose 
was changed (closed bars) or not changed (gray bars) accord-
ing to the prescribed statin type (1811 patients).
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out changing the dose (62.2%), while significantly fewer 
patients on atorvastatin (54.5%), simvastatin (43.6%), and 
fluvastatin (41.9%) received such advice (P ≤ 0.0001). 18.2% 
of patients taking rosuvastatin and 20.8% of those taking 
atorvastatin were advised to change the dose of the drug, 
while 15.8% taking simvastatin and no patient taking flu-
vastatin received such advice (for rosuvastatin vs simvasta-
tin and atorvastatin vs fluvastatin P ≤ 0.0001) (Figure 2).
disCussion
The present study showed that almost two in three pa-
tients on statin treatment in Croatia did not reach the LDL-
cholesterol target value recommended by the Fourth Joint 
European Task Force Guidelines on cardiovascular disease 
prevention in clinical practice (7). These results are worse 
than the results of EUROASPIRE III survey performed on 
13 935 patients with CHD in 22 European countries. This 
study used total cholesterol targets of <4.0 mmol/L ( ~ 155 
mg/dL) and LDL-cholesterol of <2.0 mmol/L ( ~ 80 mg/dL) 
and showed that more than two-thirds of high-risk pa-
tients had elevated total cholesterol and only one third of 
patients on lipid-lowering medication achieved the total 
cholesterol goal, while about half of them achieved LDL-
cholesterol goal (8). Croatian patients participating in this 
study had about the same results. A possible explanation 
for the differences between the studies might be that the 
present study analyzed all the patients receiving statins, 
while the EUROASPIRE III analyzed only the patients with 
proven CVD.
TASPIC-CRO survey found that 69% of 15 520 Croatian pa-
tients with CHD had elevated total and LDL-cholesterol 
(65% and 68%, respectively in the last part of this survey 
performed in 2002-2003 – TASPIC-CRO V) despite the fact 
that 57% of them were taking statins (71% in TASPIC-CRO 
V) (9). According to the more recently published CRO-
SURF survey, although 59% Croatian patients with CHD 
used statins, 57% still did not achieve target values (10). 
However, it has to be pointed out that the target value 
for total cholesterol was changed between TASPIC-CRO V 
and CRO-SURF from <5.0 mmol/L ( ~ 195 mg/dL) to <4.5 
mmol/L ( ~ 175 mg/dL). In CRO-SURF, only 68% of patients 
achieved the LDL-cholesterol level below 2.0 mmol/L 
( ~ 80 mg/dL) and the same percentage achieved the LDL-
cholesterol level <3.0 mmol/L ( ~ 115 mg/dL), which was 
the target value when TASPIC-CRO V was performed. In 
TASPIC-CRO V, 37% of patients had low HDL-cholesterol 
and in CRO-SURF study 33%, which is not significantly 
different. It is difficult to compare these studies with 
ours, since TASPIC-CRO V was finished almost a decade ago 
while CRO-SURF included considerably fewer patients and 
was a pilot study.
Apart from the mentioned studies, which had different 
aims than our study, there have been only very few cross-
sectional and cohort studies aiming to investigate the ef-
fectiveness of statin treatment similar to this one and they 
used somewhat different methodologies and approaches 
(11-13). The largest one was the recently published DYSIS 
study, which showed that 48.2% of patients treated with 
statins from 11 European countries and Canada did not 
achieve the therapeutic goal for LDL-cholesterol (14,15). 
Although this was also a disappointing result it is still bet-
ter than our findings.
On the other hand, the results of our study are similar to 
the results of A-SACT survey, which found that approxi-
mately 70% of CHD patients did not achieve the LDL-cho-
lesterol target of <2.5 mmol/L ( ~ 100 mg/dL) and approxi-
mately 94% of those with very high risk did not achieve 
<1.8 mmol/L ( ~ 70 mg/dL) (16). They are also partially 
similar to the results of a recently published CEPHEUS 
pan-Asian survey, which was performed on a very similar 
population (apart from the racial differences) according to 
age, male/female ratio, and CVD risk level (17). In this sur-
vey, however, the most commonly used statin was simvas-
tatin, followed by atorvastatin and rosuvastatin. In NCEP 
ATP III (18), the percentage of all patients who achieved 
their LDL-cholesterol goal was higher than in our study 
(49.1% vs 35.5%), but patients on rosuvastatin therapy 
were more likely to achieve target LDL-cholesterol level 
than those on other statins.
In much older L-TAP survey, the overall LDL-cholesterol 
rate of patients who reached the target level was 73%, 
ranging from 47% to 83.5% in different countries (at that 
time the goal values were much higher), while in a more 
recent CEPHEUS pan-European survey, which used the 
NCEP ATP III target values it was 57.4%, which is also much 
higher than in our study (19,20). If our study had been per-
formed after publishing of the new ESC/EAS guidelines for 
the management of dyslipidemias and the recently pub-
lished Joint European Guidelines on CVD prevention in 
clinical practice with the new LDL-cholesterol targets and 
new CVD risk stratification, our results would have been 
even worse (3,21).
When analyzing the frequency of switching to another sta-
tin or increasing the statin dose, our results could be com-
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pared with those of a German study that analyzed the data 
from an internet-based registry (22). This study showed 
that cardiologists recommended switching to another 
statin in 14.6% patients and increased the dose of statins 
in 22.9% patients. In our study, fluvastatin was almost ex-
clusively used in patients with only moderately increased 
LDL-cholesterol and therefore only a few of them needed 
to change the dose. Due to the best cholesterol-lowering 
effects of rosuvastatin, 64.2% patients treated with this sta-
tin did not need the change of the dose, while 18.2% were 
advised to change the dose and only 18.9% were advised 
to switch to other statin.
The results of the present survey indicate that the use of 
more potent statins, such as rosuvastatin and atorvasta-
tin, results in better LDL-cholesterol lowering. It seems 
that the reason for not achieving LDL-cholesterol goal in 
a great number of patients are barriers to translating evi-
dence-based data on lipid target values as recommended 
in the guidelines into routine clinical practice. The barriers 
include insufficient physicians’ knowledge of the guide-
lines, inappropriate statin choice, failure to titrate statin 
dosage adequately, lack of time and funding, but also lack 
of patients’ awareness and adherence to lipid-lowering 
therapy (23-25).
This study indicates that only about half of the patients 
treated with statins reported that they fully complied with 
the prescribed dose, while about one third of patients com-
plied with more than 70% of the prescribed dose. Although 
this does not seem low in comparison with some other sur-
veys, it has to be improved since it has been shown that a 
high level of compliance with statin therapy (80% or great-
er) is associated with progressively increasing clinical bene-
fits, both in primary and secondary CVD prevention (26-28). 
It has been also shown that patients who are very far from 
reaching serum lipid goals have the highest likelihood of 
lipid lowering medication non-adherence (29). Barriers to 
better adherence to statin treatment include the patients’ 
fear of possible adverse effects, forgetfulness, and the lack 
of belief in benefits (26). In Croatia, noncompliance could 
not be explained by drug cost or copayment, which are an 
important reason for non-adherence in some other coun-
tries, since in Croatia generic statins are fully covered by the 
compulsory health insurance (28).
This study has several limitations. One of them is that since 
this was a single-point observational study, we used cur-
rent or retrospective data from patients’ medical records. 
Lipid parameters were also taken from patients’ medical re-
cords and there was no blood sample collection and cen-
tral evaluation of lipid parameters. Another source of bias 
may be non-participation, since study participants were in-
cluded only by the cardiologists who were willing to par-
ticipate and are therefore likely to be more interested in 
treating dyslipidemia than average cardiologists.
The results of this study are worrying since they indicate 
that most patients on statin treatment fail to achieve rec-
ommended total and LDL-cholesterol target values and 
suggest the need for better treatment of dyslipidemia, par-
ticularly among high-risk patients. This could be achieved 
by improving patients’ adherence, choosing more potent 
statins and applying them in appropriate doses by ade-
quate titration of current statin treatment to higher doses, 
and the use of combined treatment (30,31,32). These might 
offer a means to increase the number of patients who meet 
their lipid target values according to the guidelines.
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